Global Neuroblastoma Drug Market will grow at $98.19 Billion by 2026- Analysis by Trends, Size, Share, and growth.

Press Release

Market Definition:

Neuroblastoma is a childhood cancer most commonly occurs in children below the age of 5 years, most often found in the small glands on top of the kidneys (adrenal glands).Neuroblastoma can develop in abdominal parts of the body where the group of nerve cells are present including chest, neck and near the spinal region. The neuroblastoma may cause due to the immature cell growth or mutation in the gene responsible for controlling cell proliferation. Neuroblastoma patient experiences symptoms such as fatigue, loss of appetite and fever. There may be a lump or compression of tissues in the affected area.

As per the April 2018 report of American Society of clinical oncology (ASCO), in the U.S. around 700 children get diagnosed with neuroblastoma every year and it indicates that amongst children younger than 1 year, neuroblastoma is the most common cancer and most frequently found in boys to that of girls.

 Market Analysis:

Global neuroblastoma drug market is rising gradually to an estimated steady CAGR of 4.2% in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017.

 A FREE sample of this report is available upon request @

Key players profiled in this report are:

Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Baxter, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, Bayer AG, MacroGenics, Inc, Advaxis, Amgen Inc, AstraZeneca, Bristol-Myers Squibb Company, Curispharma, Eli Lilly and Company, GlaxoSmithKline plc, Marsala Biotech Inc, Merck KGaA, Merck & Co. Inc, Oncolytics Biotech, Inc, ONO PHARMACEUTICAL CO. LTD, Pfizer Inc, Pierre Fabre Group, Cyclacel Pharmaceuticals, Inc, BioDiem and others.


Find More Competitor in TOC with Profile Overview Share Growth Analysis @

Major Topics Covered in this Report:

Chapter 1 Study Coverage

Chapter 2 Executive Summary

Chapter 3 Market Size by Manufacturers

Chapter 4 Production by Regions

Chapter 5 Consumption by Regions

Market Drivers & Restraints for this report:

  • Growing awareness towards diagnosis and treatment of neuroblastoma cancer drives the market growth
  • High prevalence of childhood cancers acts as a catalyst for the growth of the market
  • Increasing birth rate across the world enhances the market growth
  • Rising research on neuroblastoma treatment and increasing spending on cancer treatment elevates the market growth
  • Lack of awareness among the people about neurocarcinoma treatment hinders the market growth
  • Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth of the market
  • High cost of treatment and an adverse side effect of treatment are the major restraint of the market
  • Shortage of trained healthcare specialists is hampering the market

 10% Extra Discount for Early Buyer, Know More @

Company Share Analysis:

Global neuroblastoma drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global neuroblastoma drug market for global Europe North America, Asia-Pacific, South America and Middle East & Africa.

 Key Segments for Global Pharmaceutical Logistics Market

Mechanism of Action Type

  • Alkylating agents
  • Antimetabolites
  • Antibiotics
  • Microtubule Inhibitors
  • Monoclonal Antibodies

By Drug Type

  • Cyclophosphamide
  • Cisplatin
  • Vincristine
  • Doxorubicin
  • Etoposide
  • Topotecan
  • Busulfan
  • Melphalan

By Diagnosis Type

  • Physical Test
  • Urine and Blood Testing
  • Imaging Test
  • Tissue Sample Testing
  • Bone Marrow Sample Testing

By Treatment Type

  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Bone Marrow transplantation
  • Retinoid Therapy
  • Targeted Delivery of Radionuclides

By End users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Surgical centers
  • Others

By Geography

  • North America
    • S.
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy

Research Methodology: Global Neuroblastoma Drug Market 

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.